@article{3108304,
    title = "A prospective international Aspergillus terreus survey: an EFISG, ISHAM and ECMM joint study",
    author = "Risslegger, B. and Zoran, T. and Lackner, M. and Aigner, M. and Sánchez-Reus, F. and Rezusta, A. and Chowdhary, A. and Taj-Aldeen, S.J. and Arendrup, M.C. and Oliveri, S. and Kontoyiannis, D.P. and Alastruey-Izquierdo, A. and Lagrou, K. and Lo Cascio, G. and Meis, J.F. and Buzina, W. and Farina, C. and Drogari-Apiranthitou, M. and Grancini, A. and Tortorano, A.M. and Willinger, B. and Hamprecht, A. and Johnson, E. and Klingspor, L. and Arsic-Arsenijevic, V. and Cornely, O.A. and Meletiadis, J. and Prammer, W. and Tullio, V. and Vehreschild, J.-J. and Trovato, L. and Lewis, R.E. and Segal, E. and Rath, P.-M. and Hamal, P. and Rodriguez-Iglesias, M. and Roilides, E. and Arikan-Akdagli, S. and Chakrabarti, A. and Colombo, A.L. and Fernández, M.S. and Martin-Gomez, M.T. and Badali, H. and Petrikkos, G. and Klimko, N. and Heimann, S.M. and Houbraken, J. and Uzun, O. and Edlinger, M. and Fuente, S.D.L. and Lass-Flörl, C.",
    journal = "Clinical Microbiology and Infection",
    year = "2017",
    volume = "23",
    number = "10",
    pages = "776.e1-776.e5",
    publisher = "Elsevier B.V.",
    issn = "1198-743X",
    doi = "10.1016/j.cmi.2017.04.012",
    keywords = "amphotericin B;  amphotericin B lipid complex;  echinocandin;  pyrrole derivative;  amphotericin B;  antifungal agent, allergic bronchopulmonary aspergillosis;  antifungal susceptibility;  antifungal therapy;  Article;  aspergilloma;  aspergillosis;  Aspergillus;  Aspergillus alabamensis;  Aspergillus citrinoterreus;  Aspergillus floccosus;  Aspergillus hortai;  Aspergillus neoafricanus;  Aspergillus terreus;  chronic obstructive lung disease;  Europe;  external otitis;  human;  in vitro study;  invasive aspergillosis;  major clinical study;  Middle East;  minimum inhibitory concentration;  multicenter study;  nonhuman;  North America;  onychomycosis;  priority journal;  prospective study;  South America;  wound infection;  aspergillosis;  classification;  clinical trial;  drug effect;  epidemiological monitoring;  isolation and purification;  microbial sensitivity test;  microbiology;  prevalence, Amphotericin B;  Antifungal Agents;  Aspergillosis;  Aspergillus;  Epidemiological Monitoring;  Europe;  Humans;  Microbial Sensitivity Tests;  Prevalence;  Prospective Studies",
    abstract = "Objectives A prospective international multicentre surveillance study was conducted to investigate the prevalence and amphotericin B susceptibility of Aspergillus terreus species complex infections. Methods A total of 370 cases from 21 countries were evaluated. Results The overall prevalence of A. terreus species complex among the investigated patients with mould-positive cultures was 5.2% (370/7116). Amphotericin B MICs ranged from 0.125 to 32 mg/L, (median 8 mg/L). Conclusions Aspergillus terreus species complex infections cause a wide spectrum of aspergillosis and the majority of cryptic species display high amphotericin B MICs. © 2017"
}